CLOTTING FACTORS FROM FISH BLOOD FOR FIBRIN SEALANTS

用于纤维蛋白密封剂的鱼血凝血因子

• 批准号: 2421258
• 负责人: EVELYN SAWYER
• 金额: $ 9.78万
• 依托单位: SEA RUN HOLDINGS, INC.
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-22 至 1998-09-21
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2421258
• 关键词: animal extract; aquaculture; biomaterial development /preparation; biomaterial evaluation; blood flow measurement; clotting factor; drug design /synthesis /production; fibrin; fibrinogen; laboratory rat; method development; thrombin; trout /salmon

The overall objective of this project is to develop a medical fibrin sealant from fish plasma. Commercial aquaculture rears millions of large salmonids, and the plasma from these fish offers an unexplored and innovative source of highly conserved clotting factors. A major advantage is safety from mammalian infectious agents due to the remote phylogeny of fishes and differences in body temperature. Specific aims are to maximize fibrinogen and thrombin content of fish plasma, develop practical methods for harvest and extraction of these substances, characterize fish plasma clotting factors and a fish fibrin sealant in vitro, and conduct initial tests of this sealant in rats. Plasma fibrinogen and thrombin will be tested and compared in trout (Oncorhynchus mykiss) and salmon (Salmo salar) at different reproductive stages and under different environmental conditions, and optimum harvest conditions determined. Clot and sealant characteristics will be determined in vitro by rheologic testing and by incubation in human plasmin, and in vivo by comparing strength of rat skin incisions treated with fish fibrin sealant and a commercial sealant. PROPOSED COMMERCIAL APPLICATION: A fibrin sealant derived from fish plasma would offer safety from mammalian infectious agents, and possibly more rapid clotting, and greater clot stability. As a commercial product, it could capture a large portion of the $500 million U. S. market for fibrin sealants.

该项目的总体目标是开发一种医用纤维蛋白 从鱼血浆中提取的密封剂商业水产养殖数百万大型 鲑鱼，这些鱼的血浆提供了一个未被探索的， 高度保守的凝血因子的创新来源。一个主要优点 是安全的哺乳动物传染性病原体，由于遥远的同源性， 鱼类和体温的差异。具体目标是最大化 鱼血浆纤维蛋白原和凝血酶含量，制定实用方法 为了收获和提取这些物质， 凝血因子和鱼纤维蛋白封闭剂在体外，并进行初步 这种密封剂在老鼠身上的试验 血浆纤维蛋白原和凝血酶将测试和比较鳟鱼 （虹鳟鱼）和鲑鱼（萨尔莫salar）在不同的繁殖期 阶段和不同的环境条件下，和最佳收获 条件确定。将确定凝块和密封剂特性 通过流变学试验和在人纤溶酶中孵育体外试验， 通过比较鱼纤维蛋白处理的大鼠皮肤切口的强度， 密封剂和商业密封剂。 拟定商业应用： 从鱼血浆中提取的纤维蛋白密封剂将提供安全性， 哺乳动物感染因子，并且可能更快速地凝血， 凝块稳定性。作为一种商业产品，它可以捕获很大一部分 在5亿美元的美国S.纤维蛋白密封剂的市场。